Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18394318rdf:typepubmed:Citationlld:pubmed
pubmed-article:18394318lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18394318lifeskim:mentionsumls-concept:C0003864lld:lifeskim
pubmed-article:18394318lifeskim:mentionsumls-concept:C0392760lld:lifeskim
pubmed-article:18394318lifeskim:mentionsumls-concept:C1138802lld:lifeskim
pubmed-article:18394318pubmed:issue1lld:pubmed
pubmed-article:18394318pubmed:dateCreated2008-4-8lld:pubmed
pubmed-article:18394318pubmed:abstractTextHepatitis C Virus (HCV) infection can induce immunological disorders with different clinical expressions such as arthritis, Sjogren Syndrome and various forms of vasculitis. Retrospectively, the prevalence of anti-Cyclic Citrullinated peptide antibodies (anti-CCP) in a group of patients affected by HCV-related arthritis with positivity for Rheumatoid Factor (RF) and the eventual correlations with RF and/or Anti-Nuclear Antibodies (ANA) and articular involvement were studied. Thirty patients with arthritis were selected from a population of 380 subjects affected by HCV infection. Each patient was evaluated by clinical examination (23 denoted poliarticular and 7 mono-oligoarticular involvement), by X-graphic aspects of joint involvement (8 patients presented joint erosions), by ANA, RF and anti-CCP positivity. Ten of the HCV-related arthritis patients (33.3 percent) presented positivity for anti-CCP, without significant correlation between such parameter and ANA, RF and articular involvement. Anti-CCP resulted positive in 4 out of the 8 patients with joint erosions, and only in 6 out of the 22 patients without joint erosions. Such frequencies analyzed by chi square resulted with no significant differences. Our patients presented an interesting prevalence of the positivity for anti-CCP. These data are cause to consider the specificity recently attributed to this parameter in the diagnosis of rheumatoid arthritis.lld:pubmed
pubmed-article:18394318pubmed:languageenglld:pubmed
pubmed-article:18394318pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18394318pubmed:citationSubsetIMlld:pubmed
pubmed-article:18394318pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18394318pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18394318pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18394318pubmed:statusMEDLINElld:pubmed
pubmed-article:18394318pubmed:issn0393-974Xlld:pubmed
pubmed-article:18394318pubmed:authorpubmed-author:SpanòAAlld:pubmed
pubmed-article:18394318pubmed:authorpubmed-author:TarantinoGGlld:pubmed
pubmed-article:18394318pubmed:authorpubmed-author:RiccioAAlld:pubmed
pubmed-article:18394318pubmed:authorpubmed-author:PostiglioneLLlld:pubmed
pubmed-article:18394318pubmed:authorpubmed-author:La DoganaPPlld:pubmed
pubmed-article:18394318pubmed:authorpubmed-author:MarzocchellaC...lld:pubmed
pubmed-article:18394318pubmed:issnTypePrintlld:pubmed
pubmed-article:18394318pubmed:volume22lld:pubmed
pubmed-article:18394318pubmed:ownerNLMlld:pubmed
pubmed-article:18394318pubmed:authorsCompleteYlld:pubmed
pubmed-article:18394318pubmed:pagination57-61lld:pubmed
pubmed-article:18394318pubmed:meshHeadingpubmed-meshheading:18394318...lld:pubmed
pubmed-article:18394318pubmed:meshHeadingpubmed-meshheading:18394318...lld:pubmed
pubmed-article:18394318pubmed:meshHeadingpubmed-meshheading:18394318...lld:pubmed
pubmed-article:18394318pubmed:meshHeadingpubmed-meshheading:18394318...lld:pubmed
pubmed-article:18394318pubmed:meshHeadingpubmed-meshheading:18394318...lld:pubmed
pubmed-article:18394318pubmed:meshHeadingpubmed-meshheading:18394318...lld:pubmed
pubmed-article:18394318pubmed:meshHeadingpubmed-meshheading:18394318...lld:pubmed
pubmed-article:18394318pubmed:meshHeadingpubmed-meshheading:18394318...lld:pubmed
pubmed-article:18394318pubmed:meshHeadingpubmed-meshheading:18394318...lld:pubmed
pubmed-article:18394318pubmed:articleTitleAnti-cyclic citrullinated peptide antibodies in patients affected by HCV-related arthritis.lld:pubmed
pubmed-article:18394318pubmed:affiliationDepartment of Clinical and Experimental Medicine, Federico II University Medical School of Naples, Italy.lld:pubmed
pubmed-article:18394318pubmed:publicationTypeJournal Articlelld:pubmed